FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.
about
Recent advances in understanding and managing rhabdomyosarcomaMtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytomaInhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
P2860
FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
FANCD2 is a potential therapeu ...... ng the PAX3-FOXO1 fusion gene.
@ast
FANCD2 is a potential therapeu ...... ng the PAX3-FOXO1 fusion gene.
@en
type
label
FANCD2 is a potential therapeu ...... ng the PAX3-FOXO1 fusion gene.
@ast
FANCD2 is a potential therapeu ...... ng the PAX3-FOXO1 fusion gene.
@en
prefLabel
FANCD2 is a potential therapeu ...... ng the PAX3-FOXO1 fusion gene.
@ast
FANCD2 is a potential therapeu ...... ng the PAX3-FOXO1 fusion gene.
@en
P2093
P2860
P1476
FANCD2 is a potential therapeu ...... ing the PAX3-FOXO1 fusion gene
@en
P2093
Anthony M Vergis
Arnab Chakravarti
Brian Geier
Christopher Chronowski
Denise Fabian
Gary Woods
Justin M Leasure
Kamalakannan Palanichamy
Kathryn Bondra
Lauren A Hensley
P2860
P304
P356
10.1158/1078-0432.CCR-13-0556
P407
P577
2014-04-30T00:00:00Z